1
|
Ghammad W, Sarthou A, Dutkiewicz M, Vedie B, Neveux N, Le Guillou É, Soret L, Auditeau C, Dragon-Durey MA, Darnige L. [Pernicious anemia with false normal vitamin B12 levels caused by intrinsic factor antibodies interference: a case report]. Ann Biol Clin (Paris) 2023; 0:abc.2023.1834. [PMID: 37987415 DOI: 10.1684/abc.2023.1834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2023]
Abstract
We present a case of a 48-year-old woman with a fortuitous discovery of macrocytic anemia and thrombocytopenia. Serum folate and vitamin B12 levels were normal. However, due to the presence of indirect signs of cobalamin deficiency, such as elevated homocysteine and methylmalonic acid, and signs of dyserythropoiesis on the bone marrow aspirate, pernicious anemia was suspected. Vitamin B12 dosage was repeated finding fluctuating but always normal results. Anti-intrinsic factor antibodies were present at a very high level, explaining the fluctuations and the interference found on the assay using competitive binding chemiluminescence (CBLA). Serum vitamin B12 dosage by electrochemiluminescence, a method described as not interfering with intrinsic factor antibodies, showed a collapsed vitamin B12 level. Measurement of vitamin B12 with CBLA after adsorption of immunoglobulins in the sample using protein G SepharoseTM, confirmed the interference of the cobalamin assay with autoantibodies. This case illustrates the difficulties regarding the analysis and standardization of the vitamin B12 assay for the diagnosis of pernicious anemia.
Collapse
Affiliation(s)
- Wiame Ghammad
- Service d'Hématologie biologique, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France
| | - Aurélie Sarthou
- Service d'Hématologie biologique, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France
| | - Marion Dutkiewicz
- Service d'Hématologie biologique, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France
| | - Benoit Vedie
- Service de Biochimie, Hôpital Européen Georges-Pompidou, 20 rue Leblanc, 75015 Paris, France
| | - Nathalie Neveux
- Service de Biochimie, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
| | - Édouard Le Guillou
- Service de Biochimie, Hôpital Necker, 149 Rue de Sèvres, 75015 Paris, France
| | - Lou Soret
- Service d'Hématologie biologique, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France
| | - Claire Auditeau
- Service d'Hématologie biologique, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France
| | - Marie-Agnès Dragon-Durey
- Service d'Immunologie biologique, Hôpital Européen Georges-Pompidou, 20 rue Leblanc, 75015 Paris, France
| | - Luc Darnige
- Service d'Hématologie biologique, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France
| |
Collapse
|
2
|
Beauvais A, Gendron N, Philippe A, Vedie B, Loriot MA, Juvin P, Khider L, Sanchez O, Diehl JL, Smadja DM, Chocron R. Clinical usefulness of admission versus monitoring troponin in patients with coronavirus disease 2019. Arch Cardiovasc Dis 2023; 116:170-172. [PMID: 36710144 PMCID: PMC9851912 DOI: 10.1016/j.acvd.2022.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 12/26/2022] [Accepted: 12/28/2022] [Indexed: 01/22/2023]
Affiliation(s)
- Agathe Beauvais
- Innovative Therapies in Haemostasis, Inserm, Université Paris Cité, 75006 Paris, France; Emergency Department, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Nicolas Gendron
- Innovative Therapies in Haemostasis, Inserm, Université Paris Cité, 75006 Paris, France; Haematology Department, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Aurélien Philippe
- Innovative Therapies in Haemostasis, Inserm, Université Paris Cité, 75006 Paris, France; Haematology Department, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Benoit Vedie
- Biochemistry Department, Georges Pompidou European Hospital, AP-HP, Université de Paris, 75015 Paris, France
| | - Marie-Anne Loriot
- Biochemistry Department, Georges Pompidou European Hospital, AP-HP, Université de Paris, 75015 Paris, France
| | - Philippe Juvin
- Emergency Department, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Lina Khider
- Vascular Medicine Department, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Olivier Sanchez
- Innovative Therapies in Haemostasis, Inserm, Université Paris Cité, 75006 Paris, France; Respiratory Medicine Department, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Jean-Luc Diehl
- Innovative Therapies in Haemostasis, Inserm, Université Paris Cité, 75006 Paris, France; Medical Intensive Care Department, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - David M Smadja
- Innovative Therapies in Haemostasis, Inserm, Université Paris Cité, 75006 Paris, France; Haematology Department, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Richard Chocron
- Emergency Department, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France; Paris Cardiovascular Research Centre (PARCC), Inserm, UMR-S970, Université de Paris, 75015 Paris, France.
| |
Collapse
|
3
|
Empana JP, Lerner I, Perier MC, Guibout C, Jabre P, Bailly K, Andrieu M, Climie R, van Sloten T, Vedie B, Geromin D, Marijon E, Thomas F, Danchin N, Boutouyrie P, Jouven X. Ultrasensitive Troponin I and Incident Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2022; 42:1471-1481. [PMID: 36325900 DOI: 10.1161/atvbaha.122.317961] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND To examine the association of ultrasensitive cTnI (cardiac troponin I) with incident cardiovascular disease events (CVDs) in the primary prevention setting. METHODS cTnI was analyzed in the baseline plasma (2008-2012) of CVD-free volunteers from the Paris Prospective Study III using a novel ultrasensitive immunoassay (Simoa Troponin-I 2.0 Kit, Quanterix, Lexington) with a limit of detection of 0.013 pg/mL. Incident CVD hospitalizations (coronary heart disease, stroke, cardiac arrhythmias, deep venous thrombosis or pulmonary embolism, heart failure, or arterial aneurysm) were validated by critical review of the hospital records. Hazard ratios were estimated per log-transformed SD increase of cTnI in Cox models using age as the time scale. RESULTS The study population includes 9503 participants (40% women) aged 59.6 (6.3) years. cTnI was detected in 99.6% of the participants (median value=0.63 pg/mL, interquartile range, 0.39-1.09). After a median follow-up of 8.34 years (interquartile range, 8.0-10.07), 516 participants suffered 612 events. In fully adjusted analysis, higher cTnI (per 1 SD increase of log cTnI) was significantly associated with CVD events combined (hazard ratio, 1.18 [1.08-1.30]). Among all single risk factors, cTnI had the highest discrimination capacity for incident CVD events (C index=0.6349). Adding log cTnI to the SCORE 2 (Systematic Coronary Risk Evaluation) risk improved moderately discriminatory capacity (C index 0.698 versus 0.685; bootstrapped C index difference: 0.0135 [95% CI, 0.0131-0.0138]), and reclassification of the participants (categorical net reclassification index, 0.0628 [95% CI, 0.023-0.102]). Findings were consistent using the US pooled cohort risk equation. CONCLUSIONS Ultrasensitive cTnI is an independent marker of CVD events in the primary prevention setting.
Collapse
Affiliation(s)
- Jean-Philippe Empana
- Université Paris Cité, INSERM U970, Integrative Epidemiology of Cardiovascular Disease, France (J.-P.E., I.L., M.-C.P., C.G., P.J., R.C., T.v.S., E.M., X.J.)
| | - Ivan Lerner
- Université Paris Cité, INSERM U970, Integrative Epidemiology of Cardiovascular Disease, France (J.-P.E., I.L., M.-C.P., C.G., P.J., R.C., T.v.S., E.M., X.J.)
| | - Marie-Cécile Perier
- Université Paris Cité, INSERM U970, Integrative Epidemiology of Cardiovascular Disease, France (J.-P.E., I.L., M.-C.P., C.G., P.J., R.C., T.v.S., E.M., X.J.)
| | - Catherine Guibout
- Université Paris Cité, INSERM U970, Integrative Epidemiology of Cardiovascular Disease, France (J.-P.E., I.L., M.-C.P., C.G., P.J., R.C., T.v.S., E.M., X.J.)
| | - Patricia Jabre
- Université Paris Cité, INSERM U970, Integrative Epidemiology of Cardiovascular Disease, France (J.-P.E., I.L., M.-C.P., C.G., P.J., R.C., T.v.S., E.M., X.J.)
| | - Karine Bailly
- Université Paris Cité, INSERM U1016, Cochin Institute, Platform CYBIO, France (K.B., M.A.)
| | - Muriel Andrieu
- Université Paris Cité, INSERM U1016, Cochin Institute, Platform CYBIO, France (K.B., M.A.)
| | - Rachel Climie
- Université Paris Cité, INSERM U970, Integrative Epidemiology of Cardiovascular Disease, France (J.-P.E., I.L., M.-C.P., C.G., P.J., R.C., T.v.S., E.M., X.J.).,Menzies Institute for Medical Research, University of Tasmanian, Hobart, Australia (R.C.).,Baker Heart and Diabetes Institute, Melbourne, Australia (R.C.)
| | - Thomas van Sloten
- Université Paris Cité, INSERM U970, Integrative Epidemiology of Cardiovascular Disease, France (J.-P.E., I.L., M.-C.P., C.G., P.J., R.C., T.v.S., E.M., X.J.).,Cardiovascular Research Institute Maastricht and Department of Internal Medicine, Maastricht University Medical Centre, the Netherlands (T.v.S.)
| | - Benoit Vedie
- AP-HP, Department of Biochemistry, Tissue and Blood Samples Biobank, Georges Pompidou European Hospital, Paris, France (B.V., D.G.)
| | - Daniela Geromin
- AP-HP, Department of Biochemistry, Tissue and Blood Samples Biobank, Georges Pompidou European Hospital, Paris, France (B.V., D.G.)
| | - Eloi Marijon
- Université Paris Cité, INSERM U970, Integrative Epidemiology of Cardiovascular Disease, France (J.-P.E., I.L., M.-C.P., C.G., P.J., R.C., T.v.S., E.M., X.J.)
| | - Frederique Thomas
- Preventive and Clinical Investigation Center (IPC), Paris, France (F.T., N.D.)
| | - Nicolas Danchin
- Preventive and Clinical Investigation Center (IPC), Paris, France (F.T., N.D.)
| | - Pierre Boutouyrie
- Université Paris Cité, INSERM U970, Cellular, Molecular and Pathophysiological Mechanisms of Heart Failure, Paris, France (P.B.)
| | - Xavier Jouven
- Université Paris Cité, INSERM U970, Integrative Epidemiology of Cardiovascular Disease, France (J.-P.E., I.L., M.-C.P., C.G., P.J., R.C., T.v.S., E.M., X.J.)
| |
Collapse
|
4
|
Empana JP, Lerner I, Perier MC, Jabre P, Andrieu M, Climie RE, Van Sloten T, Vedie B, Geromin D, Marijon E, Danchin N, Thomas F, Boutouyrie P, Jouven X. Ultra-sensitive troponin-I and incident coronary heart disease, stroke, heart failure, cardiac arrhythmias, arterial aneurysms and venous thromboembolism hospitalizations. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Cardiac troponin I (cTnI) as measured by high-sensitive assays has been related to incident cardiovascular disease events (CVD) in the community. With the advent of ultra-sensitive assays, it is now possible to detect troponin I at very low concentration, far below the classical threshold of 1.9 pg/mL. However, the clinical relevance of these low concentrations for predicting CVD is largely unknown.
Purpose
To examine the association of cTnI as low as 0.013 pg/mL with incident cardiovascular disease events (CVDs) in the primary prevention setting.
Methods
cTnI was analyzed in the baseline plasma (2008–2012) of CVD free volunteers from the Paris Prospective Study III using for the first time a novel ultra-sensitive immunoassay (Simoa Troponin-I 2.0 Kit, Quanterix, Lexington) with a limit of detection (LOD) of 0.013 pg/mL. Incident CVD hospitalizations for coronary heart disease, stroke, arrhythmias, venous thromboembolism, arterial aneurysms and heart failure were validated by critical review of the hospital records. Hazard ratios were estimated per log-transformed standard deviation (SD) increase of cTnI in Cox models using age as the time scale. The added value (gain in discriminatory capacity) of cTnI for CVD risk prediction was examined by calculating the Harell's C-index boostraped difference of the SCORE 2 risk model with and without cTnI.
Results
There were 9503 CVD free participants (40% women) aged 59.6 (6.3) years at baseline. cTnI was detected in 99.6% of the participants (median value = 0.63 pg/mL, interquartile range [IQR] 0.39–1.09). After a median follow-up of 8.34 years (IQR, 8.0–10.07), 516 participants suffered 612 events. In fully-adjusted analysis, higher cTnI (per 1 SD increase of log cTnI) was significantly associated with CVD events combined (n=516, HR= 1.21; 1.06; 1.39). In univariate Cox analysis and compared to each single established risk factor, cTnI had the highest discrimination capacity for incident CVD events (C-index=0.6349) (Figure 1). Adding log cTnI to the SCORE 2 algorithm increased significantly albeit moderately discriminatory capacity (C-index 0.698 vs. 0.685; boostraped C index difference: 0.0135 (95% CI: 0.0131; 0.0138)).
Conclusion
cTnI concentrations as measured by a novel ultra-sensitive immunoassay is associated with a significant increased risk of incident CVD events in the primary prevention setting.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): ANR: French National Research AgencyEurope: Horizon 2020
Collapse
Affiliation(s)
- J P Empana
- National Institute of Health and Medical Research (INSERM home) , Paris , France
| | - I Lerner
- INSERM U970 Paris Cardiovascular Research Centre , Paris , France
| | - M C Perier
- INSERM U970 Paris Cardiovascular Research Centre , Paris , France
| | - P Jabre
- INSERM U970 Paris Cardiovascular Research Centre , Paris , France
| | - M Andrieu
- National Institute of Health and Medical Research (INSERM home) , Paris , France
| | - R E Climie
- Menzies Research Institute , Hobart , Australia
| | - T Van Sloten
- Cardiovascular Research Institute Maastricht (CARIM) , Maastricht , The Netherlands
| | - B Vedie
- Hopital Europeen Georges Pompidou-University Paris Descartes , Paris , France
| | - D Geromin
- Hopital Europeen Georges Pompidou-University Paris Descartes , Paris , France
| | - E Marijon
- INSERM U970 Paris Cardiovascular Research Centre , Paris , France
| | - N Danchin
- Hopital Europeen Georges Pompidou-University Paris Descartes , Paris , France
| | - F Thomas
- Centre d Investigations Preventives et Cliniques , Paris , France
| | - P Boutouyrie
- INSERM U970 Paris Cardiovascular Research Centre , Paris , France
| | - X Jouven
- INSERM U970 Paris Cardiovascular Research Centre , Paris , France
| |
Collapse
|
5
|
Philippe A, Puel M, Narjoz C, Gendron N, Durey-Dragon MA, Vedie B, Balduyck M, Chocron R, Hauw-Berlemont C, Sanchez O, Mirault T, Diehl JL, Smadja DM, Loriot MA. Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19. Biochimie 2022; 202:206-211. [PMID: 35952950 PMCID: PMC9359756 DOI: 10.1016/j.biochi.2022.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 07/22/2022] [Accepted: 07/22/2022] [Indexed: 12/01/2022]
Abstract
Thrombosis is a hallmark of severe COVID-19. Alpha-1-antitrypsin (AAT), an inflammation-inducible serpin with anti-inflammatory, tissue protective and anticoagulant properties may be involved in severe COVID-19 pathophysiology including thrombosis onset. In this study, we examined AAT ability to predict occurrence of thrombosis and in-hospital mortality during COVID-19. To do so, we performed a monocentric cross-sectional study of 137 hospitalized patients with COVID-19 of whom 56 (41%) were critically ill and 33 (22.4%) suffered from thrombosis during hospitalization. We measured AAT and IL-6 plasma levels in all patients and phenotyped AAT in a subset of patients with or without thrombosis paired for age, sex and COVID-19 severity. We observed that AAT levels at admission were higher in both non-survivors and thrombosis patients than in survivors and non-thrombosis patients. AAT: IL-6 ratio was lower in non-survivors and thrombosis patients. In a logistic regression multivariable analysis model adjusted on age, BMI and D-dimer levels, a higher AAT: IL-6 was a protective factor of both in-hospital mortality (Odds ratio, OR: 0.07 95%CI [0.02–0.25], p < 0.001) and thrombosis (OR 0.36 95%CI [0.14–0.82], p = 0.02). AAT phenotyping did not show a higher proportion of AAT abnormal variants in thrombosis patients.Our findings suggest an insufficient production of AAT regarding inflammation intensity during severe COVID-19. AAT appeared as a powerful predictive marker of severity, mortality and thrombosis mirroring the imbalance between harmful inflammation and protective counter-balancing mechanism in COVID-19. Restoring the balance between AAT and inflammation could offer therapeutic opportunities in severe COVID-19.
Collapse
Affiliation(s)
- Aurélien Philippe
- Université de Paris Cité, Innovative Therapies in Haemostasis, INSERM, Paris, France; Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France.
| | - Mathilde Puel
- Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Université of Paris Cité, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Céline Narjoz
- Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Université of Paris Cité, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Nicolas Gendron
- Université de Paris Cité, Innovative Therapies in Haemostasis, INSERM, Paris, France; Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Marie Agnès Durey-Dragon
- Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, Université de Paris Cité, Team Inflammation, Complement and Cancer, and Immunology Department, Georges Pompidou European Hospital, APHP-CUP, F-75015, Paris, France
| | - Benoit Vedie
- Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Université of Paris Cité, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Malika Balduyck
- CHU Lille, Laboratoire de Biochimie « Hormonologie, Metabolisme, Nutrition-Oncologie », Lille, France; CHU Lille, Univ Lille, INSERM UMR 1285, Institut de Microbiologie, Lille, France
| | - Richard Chocron
- Université de Paris Cité, PARCC, INSERM, F-75015, Emergency Department, APHP-CUP, F-75015, Paris, France
| | - Caroline Hauw-Berlemont
- Réanimation Médicale, Hôpital Européen Georges Pompidou, 26930Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| | - Olivier Sanchez
- Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Tristan Mirault
- Vascular Medicine Department and Georges Pompidou European Hospital, AP-HP, 75015, Paris, France; PARCC, INSERM, Université de Paris, 75015, Paris, France
| | - Jean-Luc Diehl
- Université de Paris Cité, Innovative Therapies in Haemostasis, INSERM, Paris, France; Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique - Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - David M Smadja
- Université de Paris Cité, Innovative Therapies in Haemostasis, INSERM, Paris, France; Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Marie Anne Loriot
- Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Université of Paris Cité, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France; INSERM UMR-S1138, Centre de recherches des Cordeliers, Paris, France.
| |
Collapse
|
6
|
Poitier B, Chocron R, Peronino C, Philippe A, Pya Y, Rivet N, Richez U, Bekbossynova M, Gendron N, Grimmé M, Bories MC, Brichet J, Capel A, Rancic J, Vedie B, Roussel JC, Jannot AS, Jansen P, Carpentier A, Ivak P, Latremouille C, Netuka I, Smadja DM. Bioprosthetic Total Artificial Heart in Autoregulated Mode Is Biologically Hemocompatible: Insights for Multimers of von Willebrand Factor. Arterioscler Thromb Vasc Biol 2022; 42:470-480. [PMID: 35139659 DOI: 10.1161/atvbaha.121.316833] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
BACKGROUND Carmat bioprosthetic total artificial heart (Aeson; A-TAH) is a pulsatile and autoregulated device. The aim of this study is to evaluate level of hemolysis potential acquired von Willebrand syndrome after A-TAH implantation. METHODS We examined the presence of hemolysis and acquired von Willebrand syndrome in adult patients receiving A-TAH support (n=10) during their whole clinical follow-up in comparison with control subjects and adult patients receiving Heartmate II or Heartmate III support. We also performed a fluid structure interaction model coupled with computational fluid dynamics simulation to evaluate the A-TAH resulting shear stress and its distribution in the blood volume. RESULTS The cumulative duration of A-TAH support was 2087 days. A-TAH implantation did not affect plasma free hemoglobin over time, and there was no association between plasma free hemoglobin and cardiac output or beat rate. For VWF (von Willebrand factor) evaluation, A-TAH implantation did not modify multimers profile of VWF in contrast to Heartmate II and Heartmate III. Furthermore, fluid structure interaction coupled with computational fluid dynamics showed a gradually increase of blood damage according to increase of cardiac output (P<0.01), however, the blood volume fraction that endured significant shear stresses was always inferior to 0.03% of the volume for both ventricles in all regimens tested. An inverse association between cardiac output, beat rate, and high-molecular weight multimers ratio was found. CONCLUSIONS We demonstrated that A-TAH does not cause hemolysis or AWVS. However, relationship between HMWM and cardiac output depending flow confirms relevance of VWF as a biological sensor of blood flow, even in normal range.
Collapse
Affiliation(s)
- Bastien Poitier
- Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.).,Cardiac Surgery Department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (B.P., A.C., C.L.).,Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.)
| | - Richard Chocron
- Université de Paris, PARCC, INSERM, F-75015 Paris, France, Emergency department, AP-HP, Georges Pompidou European Hospital, France (R.C.)
| | - Christophe Peronino
- Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
| | - Aurélien Philippe
- Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
| | - Yuri Pya
- National Research Cardiac, Surgery Center, Nur-Sultan, Kazakhstan (Y.P., M.B.)
| | - Nadia Rivet
- Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
| | - Ulysse Richez
- Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.).,Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
| | | | - Nicolas Gendron
- Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
| | - Marc Grimmé
- Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.)
| | - Marie Cécile Bories
- Université de Paris, Cardiac Surgery Department, AP-HP, Georges Pompidou European Hospital, France (M.C.B.)
| | - Julie Brichet
- Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
| | - Antoine Capel
- Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.).,Cardiac Surgery Department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (B.P., A.C., C.L.)
| | - Jeanne Rancic
- Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
| | - Benoit Vedie
- AP-HP, Biochemistry Department, Georges Pompidou European Hospital, France (B.V.)
| | - Jean Christian Roussel
- Cardiac and thoracic Surgery Department, CHU de Nantes, hôpital Nord Laënnec, boulevard Jacques-Monod, France (J.C.R.)
| | - Anne-Sophie Jannot
- Department of Bioinformatics, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France (A.-S.J.)
| | | | - Alain Carpentier
- Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.)
| | - Peter Ivak
- Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.I., I.N.)
| | - Christian Latremouille
- Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.).,Cardiac Surgery Department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (B.P., A.C., C.L.)
| | - Ivan Netuka
- Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.I., I.N.)
| | - David M Smadja
- Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
| |
Collapse
|
7
|
Wack M, Péré H, Demory-Guinet N, Kassis-Chikhani N, Janot L, Vedie B, Izquierdo L, Bélec L, Veyer D. No SARS-CoV-2 reinfection among staff health-care workers: Prospective hospital-wide screening during the first and second waves in Paris. J Clin Virol 2021; 145:104999. [PMID: 34695725 PMCID: PMC8525071 DOI: 10.1016/j.jcv.2021.104999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 09/28/2021] [Accepted: 10/16/2021] [Indexed: 11/27/2022]
Abstract
Objectives Risk of reinfection with SARS-CoV-2 among health-care workers (HCWs) is unknown. We assessed the incidence rate of SARS-CoV-2 reinfection in the real-life setting of a longitudinal observational cohort of HCWs from the Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, France, during the first and second waves of COVID-19 epidemic. Methods From March to December 2020, HCWs were subjected to molecular and serology testing of SARS-CoV-2. Reinfection was defined as a positive test result during the first wave, either by serology or PCR, followed by a positive PCR during the second wave. Evolution of COVID-19 status of HWCs was assessed by a Sankey diagram. Results A total of 7765 tests (4579 PCR and 3186 serology) were carried out and 4168 HCWs had at least one test result during the follow-up period with a positivity rate of 15.9%. No case of reinfection during the second wave could be observed among 102 positive HCWs of the first wave, nor among 175 HCWs found positive by PCR during the second wave who were negative during the first wave. Conclusions SARS-CoV-2 reinfection was not observed among HCWs, suggesting a protective immunity against reinfection that lasts at least 8 months post infection.
Collapse
Affiliation(s)
- Maxime Wack
- Département d'Informatique Médicale, Biostatistiques et Santé Publique, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France; Faculté de Médecine, Université de Paris, Paris, 75005, France
| | - Hélène Péré
- Laboratoire de Virologie, Service de Microbiologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France; Unité de Génomique Fonctionnelle des Tumeurs Solides, Centre de Recherche des Cordeliers, INSERM, Université Paris, Paris, 75005, France
| | - Nathalie Demory-Guinet
- Service de Médecine du Travail, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France
| | - Najiby Kassis-Chikhani
- Unité d'Hygiène Hospitalière, Service de Microbiologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France
| | - Laurence Janot
- Service de Médecine du Travail, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France
| | - Benoit Vedie
- Laboratoire de Biochimie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France
| | - Laure Izquierdo
- Laboratoire de Virologie, Service de Microbiologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France
| | - Laurent Bélec
- Faculté de Médecine, Université de Paris, Paris, 75005, France; Laboratoire de Virologie, Service de Microbiologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France; INSERM U970, PARCC, hôpital européen Georges Pompidou, Faculté de Médecine, Université de Paris, Paris, 75015, France
| | - David Veyer
- Laboratoire de Virologie, Service de Microbiologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France; Unité de Génomique Fonctionnelle des Tumeurs Solides, Centre de Recherche des Cordeliers, INSERM, Université Paris, Paris, 75005, France.
| |
Collapse
|
8
|
McCarthy C, Bugnet E, Benattia A, Keane MP, Vedie B, Lorillon G, Tazi A. Clarifying the relationship between pulmonary langerhans cell histiocytosis and Alpha 1 antitrypsin deficiency. Orphanet J Rare Dis 2021; 16:72. [PMID: 33563302 PMCID: PMC7871552 DOI: 10.1186/s13023-021-01720-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Accepted: 02/01/2021] [Indexed: 11/26/2022] Open
Abstract
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare, smoking related, progressive diffuse cystic lung disease that occurs primarily in smokers. The aim of this study was to determine if there was an increase in alpha-1 antitrypsin deficient alleles or phenotypes in a large series of PLCH patients and whether serum alpha-1 antitrypsin levels correlated with markers of disease severity. Fifty PLCH patients, 24 with a diffuse cystic lung pattern and 26 with a typical nodulo-cystic pattern on imaging were included. The mean alpha-1 antitrypsin levels were in normal range for both the population with diffuse cystic lung pattern population (1.39 g/L ± 0.37) and the nodulo-cystic pattern group (1.41 g/L ± 0.21). Deficiency alleles PiZ and PiS were 1% and 2% respectively in the entire study population of 50 patients, demonstrating no increased incidence of alpha-1 antitrypsin deficiency in PLCH. Alpha-1 antitrypsin levels showed no correlation with lung function parameters or extent of cystic lesions on lung computed tomography.
Collapse
Affiliation(s)
- Cormac McCarthy
- Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin 4, Ireland.,School of Medicine, University College Dublin, Dublin 4, Ireland
| | - Emmanuelle Bugnet
- Hôpital Saint-Louis, Centre National de Référence des Histiocytoses, Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Amira Benattia
- Hôpital Saint-Louis, Centre National de Référence des Histiocytoses, Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Michael P Keane
- Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin 4, Ireland.,School of Medicine, University College Dublin, Dublin 4, Ireland
| | - Benoit Vedie
- Hôpital Européen Georges Pompidou, Service de Biochimie, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Gwenaël Lorillon
- Hôpital Saint-Louis, Centre National de Référence des Histiocytoses, Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Abdellatif Tazi
- Hôpital Saint-Louis, Centre National de Référence des Histiocytoses, Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Paris, France. .,Université de Paris, INSERM U976, Institut de Recherche Saint-Louis, 75006, Paris, France. .,Centre National de Référence des Histiocytoses, Service de Pneumologie, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75475, Paris Cedex 10, France.
| |
Collapse
|
9
|
Goudot G, Chocron R, Augy JL, Gendron N, Khider L, Debuc B, Aissaoui N, Peron N, Hauw-Berlemont C, Vedie B, Cheng C, Mohamedi N, Krzisch D, Philippe A, Puscas T, Hermann B, Brichet J, Juvin P, Planquette B, Messas E, Pere H, Veyer D, Gaussem P, Sanchez O, Diehl JL, Mirault T, Smadja DM. Predictive Factor for COVID-19 Worsening: Insights for High-Sensitivity Troponin and D-Dimer and Correlation With Right Ventricular Afterload. Front Med (Lausanne) 2020; 7:586307. [PMID: 33282891 PMCID: PMC7689153 DOI: 10.3389/fmed.2020.586307] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 09/29/2020] [Indexed: 12/16/2022] Open
Abstract
Background: Coronavirus disease 2019 (COVID-19) has been associated with cardiovascular complications and coagulation disorders. Objectives: To explore clinical and biological parameters of COVID-19 patients with hospitalization criteria that could predict referral to intensive care unit (ICU). Methods: Analyzing the clinical and biological profiles of COVID-19 patients at admission. Results: Among 99 consecutive patients that fulfilled criteria for hospitalization, 48 were hospitalized in the medicine department, 21 were first admitted to the medicine ward department and referred later to ICU, and 30 were directly admitted to ICU from the emergency department. At admission, patients requiring ICU were more likely to have lymphopenia, decreased SpO2, a D-dimer level above 1,000 ng/mL, and a higher high-sensitivity cardiac troponin (Hs-cTnI) level. A receiver operating characteristic curve analysis identified Hs-cTnI above 9.75 pg/mL as the best predictive criteria for ICU referral [area under the curve (AUC), 86.4; 95% CI, 76.6–96.2]. This cutoff for Hs-cTnI was confirmed in univariate [odds ratio (OR), 22.8; 95% CI, 6.0–116.2] and multivariate analysis after adjustment for D-dimer level (adjusted OR, 20.85; 95% CI, 4.76–128.4). Transthoracic echocardiography parameters subsequently measured in 72 patients showed an increased right ventricular (RV) afterload correlated with Hs-cTnI (r = 0.42, p = 0.010) and D-dimer (r = 0.18, p = 0.047). Conclusion: Hs-cTnI appears to be the best relevant predictive factor for referring COVID-19 patients to ICU. This result associated with the correlation of D-dimer with RV dilatation probably reflects a myocardial injury due to an increased RV wall tension. This reinforces the hypothesis of a COVID-19-associated microvascular thrombosis inducing a higher RV afterload.
Collapse
Affiliation(s)
- Guillaume Goudot
- Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Richard Chocron
- PARCC, INSERM, Université de Paris, Paris, France.,Emergency Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Jean-Loup Augy
- Intensive Care Unit, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Nicolas Gendron
- Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.,Haematology Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Lina Khider
- Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Benjamin Debuc
- Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.,Plastic Surgery Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Nadia Aissaoui
- Intensive Care Unit, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Nicolas Peron
- Intensive Care Unit, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Caroline Hauw-Berlemont
- Intensive Care Unit, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Benoit Vedie
- Biochemistry Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Charles Cheng
- Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Nassim Mohamedi
- Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Daphné Krzisch
- Haematology Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Aurélien Philippe
- Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.,Haematology Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Tania Puscas
- Intensive Care Unit, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Bertrand Hermann
- Intensive Care Unit, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Julie Brichet
- Haematology Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Philippe Juvin
- Emergency Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Benjamin Planquette
- Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.,Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Emmanuel Messas
- Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France.,PARCC, INSERM, Université de Paris, Paris, France
| | - Hélène Pere
- PARCC, INSERM, Université de Paris, Paris, France.,Virology Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - David Veyer
- Virology Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France.,Centre de Recherche des Cordeliers, Functional Genomics of Solid Tumors, INSERM, Université de Paris, Paris, France
| | - Pascale Gaussem
- Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.,Haematology Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Olivier Sanchez
- Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.,Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Jean-Luc Diehl
- Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.,Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| | - Tristan Mirault
- Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France.,PARCC, INSERM, Université de Paris, Paris, France
| | - David M Smadja
- Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.,Haematology Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France
| |
Collapse
|
10
|
Looten V, Kong Win Chang L, Neuraz A, Landau-Loriot MA, Vedie B, Paul JL, Mauge L, Rivet N, Bonifati A, Chatellier G, Burgun A, Rance B. What can millions of laboratory test results tell us about the temporal aspect of data quality? Study of data spanning 17 years in a clinical data warehouse. Comput Methods Programs Biomed 2019; 181:104825. [PMID: 30612785 DOI: 10.1016/j.cmpb.2018.12.030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Revised: 12/24/2018] [Accepted: 12/28/2018] [Indexed: 06/09/2023]
Abstract
OBJECTIVE To identify common temporal evolution profiles in biological data and propose a semi-automated method to these patterns in a clinical data warehouse (CDW). MATERIALS AND METHODS We leveraged the CDW of the European Hospital Georges Pompidou and tracked the evolution of 192 biological parameters over a period of 17 years (for 445,000 + patients, and 131 million laboratory test results). RESULTS We identified three common profiles of evolution: discretization, breakpoints, and trends. We developed computational and statistical methods to identify these profiles in the CDW. Overall, of the 192 observed biological parameters (87,814,136 values), 135 presented at least one evolution. We identified breakpoints in 30 distinct parameters, discretizations in 32, and trends in 79. DISCUSSION AND CONCLUSION our method allowed the identification of several temporal events in the data. Considering the distribution over time of these events, we identified probable causes for the observed profiles: instruments or software upgrades and changes in computation formulas. We evaluated the potential impact for data reuse. Finally, we formulated recommendations to enable safe use and sharing of biological data collection to limit the impact of data evolution in retrospective and federated studies (e.g. the annotation of laboratory parameters presenting breakpoints or trends).
Collapse
Affiliation(s)
- Vincent Looten
- INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Hôpital Européen Georges Pompidou, Department of Medical Informatics, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes, 20 rue Leblanc, 75015 Paris, France
| | | | - Antoine Neuraz
- INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Hôpital Necker - Enfants Malades, Department of Medical Informatics, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes, France
| | - Marie-Anne Landau-Loriot
- Hôpital Européen Georges Pompidou, Department of Biochimistry, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes, France
| | - Benoit Vedie
- Hôpital Européen Georges Pompidou, Department of Biochimistry, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes, France
| | - Jean-Louis Paul
- Hôpital Européen Georges Pompidou, Department of Biochimistry, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes, France
| | - Laëtitia Mauge
- Hôpital Européen Georges Pompidou, Department of Hematology, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes, France
| | - Nadia Rivet
- Hôpital Européen Georges Pompidou, Department of Hematology, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes, France
| | - Angela Bonifati
- LIRIS UMR CNRS 5205, Université Claude Bernard Lyon 1, Villeurbanne, France
| | - Gilles Chatellier
- Hôpital Européen Georges Pompidou, Department of Medical Informatics, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes, 20 rue Leblanc, 75015 Paris, France
| | - Anita Burgun
- INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Hôpital Européen Georges Pompidou, Department of Medical Informatics, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes, 20 rue Leblanc, 75015 Paris, France; Hôpital Necker - Enfants Malades, Department of Medical Informatics, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes, France
| | - Bastien Rance
- INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Hôpital Européen Georges Pompidou, Department of Medical Informatics, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Descartes, 20 rue Leblanc, 75015 Paris, France.
| |
Collapse
|
11
|
Fournier N, Benoist J, Allaoui F, Nowak M, Sayet G, Vedie B, Paul J. Polyunsaturated fatty acids (PUFAs) differentially affected abca1-mediated cholesterol efflux from cholesterol-loaded mouse or human macrophages. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
12
|
Fournier N, Travers S, Passet M, Sserve P, Girard E, Vedie B, Paul J. Autophagy is not required for abca1-mediated cholesterol efflux in cholesterol loaded human monocyte-derived macrophages. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.531] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
13
|
Fournier N, Reboulleau A, Robert V, Vedie B, Paul JL, Grynberg A. 140 IMPACT OF OMEGA 3 AND OMEGA 6 FATTY ACIDS MEMBRANE INCORPORATION ON CHOLESTEROL EFFLUX FROM CULTURED RAT CARDIOMYOCYTES. ATHEROSCLEROSIS SUPP 2011. [DOI: 10.1016/s1567-5688(11)70141-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
Sinha B, Köster D, Ruez R, Gonnord P, Bastiani M, Abankwa D, Stan RV, Butler-Browne G, Vedie B, Johannes L, Morone N, Parton RG, Raposo G, Sens P, Lamaze C, Nassoy P. Cells respond to mechanical stress by rapid disassembly of caveolae. Cell 2011; 144:402-13. [PMID: 21295700 DOI: 10.1016/j.cell.2010.12.031] [Citation(s) in RCA: 634] [Impact Index Per Article: 48.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2010] [Revised: 10/27/2010] [Accepted: 12/23/2010] [Indexed: 12/15/2022]
Abstract
The functions of caveolae, the characteristic plasma membrane invaginations, remain debated. Their abundance in cells experiencing mechanical stress led us to investigate their role in membrane-mediated mechanical response. Acute mechanical stress induced by osmotic swelling or by uniaxial stretching results in a rapid disappearance of caveolae, in a reduced caveolin/Cavin1 interaction, and in an increase of free caveolins at the plasma membrane. Tether-pulling force measurements in cells and in plasma membrane spheres demonstrate that caveola flattening and disassembly is the primary actin- and ATP-independent cell response that buffers membrane tension surges during mechanical stress. Conversely, stress release leads to complete caveola reassembly in an actin- and ATP-dependent process. The absence of a functional caveola reservoir in myotubes from muscular dystrophic patients enhanced membrane fragility under mechanical stress. Our findings support a new role for caveolae as a physiological membrane reservoir that quickly accommodates sudden and acute mechanical stresses.
Collapse
|
15
|
Fournier N, Attia N, Rousseau D, Vedie B, Destaillats F, Grynberg A, Paul JL. P302 TRANS ELAIDIC BUT NOT VACCENIC ACID IMPAIRS ABCA1-DEPENDENT CHOLESTEROL EFFLUX FROM J774 MACROPHAGES. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)70369-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Attia N, Fournier N, Vedie B, Cambillau M, Grynberg A, Paul JL, Guerci B. Abstract: P422 IMPACT OF ANDROID OBESITY AND INSULIN RESISTANCE ON BASAL AND POSTPRANDIAL SR-BI AND ABCA1-MEDIATED SERUM CHOLESTEROL EFFLUX CAPACITIES. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)70717-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
17
|
Catalano G, Julia Z, Frisdal E, Vedie B, Fournier N, Le Goff W, Chapman MJ, Guerin M. Torcetrapib Differentially Modulates the Biological Activities of HDL2 and HDL3 Particles in the Reverse Cholesterol Transport Pathway. Arterioscler Thromb Vasc Biol 2009; 29:268-75. [DOI: 10.1161/atvbaha.108.179416] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Giovanna Catalano
- From INSERM UMRS551 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; Université Pierre et Marie Curie–Paris6 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; AP-HP, Hôpital Européen Georges Pompidou (B.V., N.F.), Service de biochimie, Paris; and Univ Paris-Sud (N.F.), UMR INRA 1154, UFR de Pharmacie, Châtenay-Malabry, France
| | - Zélie Julia
- From INSERM UMRS551 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; Université Pierre et Marie Curie–Paris6 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; AP-HP, Hôpital Européen Georges Pompidou (B.V., N.F.), Service de biochimie, Paris; and Univ Paris-Sud (N.F.), UMR INRA 1154, UFR de Pharmacie, Châtenay-Malabry, France
| | - Eric Frisdal
- From INSERM UMRS551 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; Université Pierre et Marie Curie–Paris6 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; AP-HP, Hôpital Européen Georges Pompidou (B.V., N.F.), Service de biochimie, Paris; and Univ Paris-Sud (N.F.), UMR INRA 1154, UFR de Pharmacie, Châtenay-Malabry, France
| | - Benoit Vedie
- From INSERM UMRS551 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; Université Pierre et Marie Curie–Paris6 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; AP-HP, Hôpital Européen Georges Pompidou (B.V., N.F.), Service de biochimie, Paris; and Univ Paris-Sud (N.F.), UMR INRA 1154, UFR de Pharmacie, Châtenay-Malabry, France
| | - Natalie Fournier
- From INSERM UMRS551 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; Université Pierre et Marie Curie–Paris6 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; AP-HP, Hôpital Européen Georges Pompidou (B.V., N.F.), Service de biochimie, Paris; and Univ Paris-Sud (N.F.), UMR INRA 1154, UFR de Pharmacie, Châtenay-Malabry, France
| | - Wilfried Le Goff
- From INSERM UMRS551 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; Université Pierre et Marie Curie–Paris6 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; AP-HP, Hôpital Européen Georges Pompidou (B.V., N.F.), Service de biochimie, Paris; and Univ Paris-Sud (N.F.), UMR INRA 1154, UFR de Pharmacie, Châtenay-Malabry, France
| | - M. John Chapman
- From INSERM UMRS551 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; Université Pierre et Marie Curie–Paris6 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; AP-HP, Hôpital Européen Georges Pompidou (B.V., N.F.), Service de biochimie, Paris; and Univ Paris-Sud (N.F.), UMR INRA 1154, UFR de Pharmacie, Châtenay-Malabry, France
| | - Maryse Guerin
- From INSERM UMRS551 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; Université Pierre et Marie Curie–Paris6 (G.C., Z.J., E.F., W.L.G., M.J.C., M.G.), Hôpital de la Pitié, Paris; AP-HP, Hôpital Européen Georges Pompidou (B.V., N.F.), Service de biochimie, Paris; and Univ Paris-Sud (N.F.), UMR INRA 1154, UFR de Pharmacie, Châtenay-Malabry, France
| |
Collapse
|
18
|
Rossi GP, Taddei S, Ghiadoni L, Virdis A, Zavattiero S, Favilla S, Versari D, Sudano I, Azizi M, Vedie B, Pessina AC, Salvetti A, Jeunemaitre X. Tissue kallikrein gene polymorphisms induce no change in endothelium-dependent or independent vasodilation in hypertensive and normotensive subjects. J Hypertens 2006; 24:1955-63. [PMID: 16957554 DOI: 10.1097/01.hjh.0000244943.34546.40] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Tissue kallikrein (TK) generates Lys-bradykinin, which is then converted to bradykinin and releases nitric oxide (NO) from endothelial cells via B2 receptors. TK gene inactivation in mice causes severe endothelial dysfunction, which is also a hallmark of human primary hypertension (PH). Healthy carriers of a loss-of-function Arg to His substitution at position 53 (R53H) of the TK gene exhibit paradoxical arterial eutrophic remodeling. We therefore investigated the impact of this and other TK gene single nucleotide polymorphisms (SNPs) on endothelium-dependent vasodilatation (EDV) and endothelium-independent vasodilatation (EIV) in PH patients and normotensive (NT) subjects. METHODS The TK gene SNPs were genotyped blind to the phenotype by sequencing. We compared EDV and EIV vasodilatation across TK genotypes in 131 uncomplicated PH patients and 51 healthy NT subjects. EDV and EIV were assessed as the forearm blood flow response to a graded infusion of acetylcholine and sodium nitroprusside, respectively. We also evaluated the impact of the SNPs on NO-mediated EDV and on reactive oxygen species (ROS)-induced NO breakdown with the nitric oxide synthase (NOS) inhibitor N(G)-monomethyl-L-arginine or vitamin C, respectively. RESULTS Genotypes and allele frequencies were in Hardy-Weinberg equilibrium and similar in PH and NT. EDV was lower in PH patients than in NT subjects. No TK genotype affected either EDV or EIV per se, or via interaction with gender and age. NO inhibition and scavenging of ROS showed no TK genotype effect on EDV. Similar conclusions were obtained with haplotype analysis. CONCLUSIONS These results do not support the contention that TK gene SNPs have a major impact in determining NO-mediated responses to acetylcholine.
Collapse
|
19
|
Robinet P, Fradagrada A, Monier MN, Marchetti M, Cogny A, Moatti N, Paul JL, Vedie B, Lamaze C. Dynamin is involved in endolysosomal cholesterol delivery to the endoplasmic reticulum: role in cholesterol homeostasis. Traffic 2006; 7:811-23. [PMID: 16787396 DOI: 10.1111/j.1600-0854.2006.00435.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Cholesterol is one of the most essential membrane components in mammalian cells and plays a critical role in several cellular functions. It is now established that intracellular cholesterol transport contributes to the regulation of cellular cholesterol homeostasis by mechanisms that are yet poorly defined. In this study, we examined the role of clathrin- and dynamin-dependent trafficking on the regulatory machinery involved in cholesterol homeostasis. Thus, expression levels of three major sterol-sensitive genes, that is sterol-regulatory element binding protein 2 (SREBP-2), hydroxymethylglutaryl-coenzyme A (HMGCoA) reductase and low-density lipoprotein (LDL) receptor, were monitored to study the cell response to the addition of LDL-derived cholesterol. We found that inhibition of clathrin-dependent endocytosis had no effect on the intracellular distribution of cholesterol and the regulation of sterol-sensitive genes. In contrast, inhibition of dynamin activity resulted in the lack of regulation of SREBP-2, HMGCoA reductase and LDL receptor genes. Immunolocalization studies along with the measure of free and esterified cholesterol indicated that dynamin inactivation led to the accumulation of free cholesterol (FC) within the late endosomal (LE)/lysosomal compartment resulting in insufficient delivery of regulatory cholesterol to the endoplasmic reticulum (ER) where the transcriptional control of sterol-sensitive genes occurs. Our data therefore indicate that dynamin plays a critical role in the delivery of cholesterol from the LE/lysosomal network to the ER and highlight the importance of LE trafficking in cholesterol homeostasis.
Collapse
Affiliation(s)
- Peggy Robinet
- Laboratoire de Biochimie Appliquée, UFR de Pharmacie, Châtenay-Malabry, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Fournier N, Atger V, Cogny A, Vedie B, Giral P, Simon A, Moatti N, Paul JL. Analysis of the relationship between triglyceridemia and HDL-phospholipid concentrations: consequences on the efflux capacity of serum in the Fu5AH system. Atherosclerosis 2001; 157:315-23. [PMID: 11472731 DOI: 10.1016/s0021-9150(00)00730-9] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The high triglyceride/low HDL-cholesterol trait is a common finding in the general population. The aim of the present study was to analyze and interpret the relationships between triglycerides (TG), HDL-related parameters and serum cholesterol efflux potential in an asymptomatic population including both normo- and hyperlipidemic individuals. In a large sample (n = 1143) of this population, there was a negative correlation between TG and HDL-cholesterol (HDL-C) (r = -0.49, P<0.0001) whereas the negative correlation between TG and HDL-phospholipid (HDL-PL) (r = -0.29, P<0.0001) was weaker, leading to a strong positive correlation between TG and HDL-PL/C ratio (r = 0.58, P<0.0001). Thus, increased TG concentrations were associated with an enrichment of HDL with PL. Since we have demonstrated previously that HDL-PL is the major determinant for cholesterol efflux potential from Fu5AH rat hepatoma cells, we determined the effect of the variations in HDL lipid composition on the cholesterol efflux capacity in a subsample of 198 subjects. Compared with normolipidemic subjects (NLP) (TG< or = 1.7 mmol/l; LDL-C< or = 4.1 mmol/l, n=58), hypertriglyceridemic subjects (HTG) (TG>1.7 mmol/l, n=63) exhibited lower HDL-C levels (1.08+/-0.21 vs. 1.25+/-0.32, P=0.0003) whereas they showed similar HDL-PL concentrations (1.25+/-0.21 vs. 1.25+/-2.7) and, thus, higher HDL-PL/C ratio (1.17+/-0.15 vs. 1.02+/-0.14, P=0.0001). The relative efflux capacity of serum measured in the Fu5AH system (5% serum, 4 h incubation at 37 degrees C) was on average identical in the HTG and NLP groups. Thus, this study provides evidence that despite decreased HDL concentrations, as determined routinely by the HDL-C assay, some HTG subjects maintained serum cholesterol efflux capacity thanks to the enrichment of HDL with PL.
Collapse
Affiliation(s)
- N Fournier
- Laboratoire de Biochimie Appliquée, Faculté des Sciences Pharmaceutiques et Biologiques, Châtenay-Malabry, France.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Vuagnat A, Giacché M, Hopkins PN, Azizi M, Hunt SC, Vedie B, Corvol P, Williams GH, Jeunemaitre X. Blood pressure response to angiotensin II, low-density lipoprotein cholesterol and polymorphisms of the angiotensin II type 1 receptor gene in hypertensive sibling pairs. J Mol Med (Berl) 2001; 79:175-83. [PMID: 11409708 DOI: 10.1007/s001090100205] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Blood pressure (BP) response to infused angiotensin II (Ang II) has been widely used to characterize hypertensive subjects. High cholesterol levels have recently been found to enhance this response in young men, suggesting an important new link between atherosclerosis and hypertension. The present study assessed the familial resemblance of the BP response following an Ang II infusion and measured the factors affecting the trait in a large set of hypertensive men and women. After a low-salt diet for 7 days a 30-min infusion of Ang II was administered to 218 white hypertensive patients (28 singletons, 80 sibling pairs, 10 trios). Age and gender were significantly correlated to the Ang II systolic but not to the diastolic BP response. Conversely, cholesterol level and especially low-density lipoprotein (LDL) were correlated to both systolic and diastolic changes. Multivariate analysis showed that age, gender, and LDL were the three parameters that explained the systolic BP change whereas plasma LDL remained the only variable significantly correlated to the diastolic BP change. Significant familial resemblances in the Ang II induced systolic and diastolic BP response were observed, especially in female pairs. On this limited number of subjects, suggestive evidence for association and linkage was found between the trait, A1166C, and (CA)n repeat polymorphisms of the Ang II type 1 receptor (AT1R) gene. In conclusion, the Ang II induced BP change is strongly related to plasma LDL in hypertensive men and women, stressing the importance of the lipid profile as a contributor to BP regulation. Familial resemblance of this intermediate phenotype is sex dependent and may be partly explained by polymorphisms of the AT1R gene.
Collapse
Affiliation(s)
- A Vuagnat
- Department of Hypertension, Hĵpital Européen Georges Pompidou, INSERM U36 College de France, Paris
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Pico I, Myara I, Pech-Amsellem MA, Vedie B, Chappey B, Moatti N. Oxidative modification of low-density lipoprotein by the human hepatoma cell line HepG2. Free Radic Res 1996; 25:321-36. [PMID: 8889496 DOI: 10.3109/10715769609149055] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The human hepatoblastoma cell line HepG2 is a liver model commonly used for lipid metabolism studies. Numerous cell types have been found to oxidize low-density lipoprotein (LDL) but, to our knowledge, the effects of HepG2 cells on LDL have not been investigated. We found that LDL is modified by HepG2 cells through a peroxidative mechanism, as judged by an increase in TBARS content (which was prevented in the presence of the antioxidants vitamin E, 2,6-di-tertbutyl-cresol and probucol), increased degradation by J774 macrophages, decreased internalization by MRC5 fibroblasts, and aggregation of apo B. Aspirin and allopurinol, which inhibit cyclooxygenase and xanthine-oxidase activities, respectively, had no effect on HepG2-induced LDL modification, and neither did catalase, which dismutates hydrogen peroxide; or mannitol, which scavenges hydroxyl radicals. In contrast, superoxide dismutase, a superoxide anion scavenger, and glutamate and threonine, which alter cellular cystine uptake, prevented LDL modifications, as did the removal of cysteine/cystine from the culture medium. Oxidation of LDL by HepG2 cells might thus involve superoxide anion production and/or thiol metabolism.
Collapse
Affiliation(s)
- I Pico
- Laboratoire de Biochimie Appliquée des Sciences Pharmaceutiques et Biologiques, Châtenay-Malabry, France
| | | | | | | | | | | |
Collapse
|
23
|
Demuth K, Myara I, Chappey B, Vedie B, Pech-Amsellem MA, Haberland ME, Moatti N. A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol 1996; 16:773-83. [PMID: 8640405 DOI: 10.1161/01.atv.16.6.773] [Citation(s) in RCA: 81] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
By using fast protein liquid chromatography, we isolated from human plasma a minor electronegative LDL subfraction designated LDL(-). After immunoaffinity chromatography against apolipoprotein (apo)(a) and apo A-I, LDL(-) represented 6.7 +/- 0.9% (mean +/- SD; n = 18) of total LDL. Compared with the major LDL subfraction, designated LDL(+), LDL(-) contained similar amounts of thiobarbituric acid-reactive substances, conjugated dienes, and vitamin E and had a similar lipid/protein ratio and mean density. Moreover, the apo B of LDL(-) was not aggregated and its LDL receptor-binding activity was slightly increased. These results were consistent with the nonoxidized nature of LDL(-). LDL(-) showed increased contents of sialic acid (38.1 +/- 5.2 versus 28.9 +/- 3.3 nmol/mg protein; n = 7; P < .01), apo C-III (1.43 +/- 0.21% versus 0.14 +/- 0.04%; n = 7; P < .01), and apo E (1.64 +/- 0.26% versus 0.10 +/- 0.05%; n = 7; P < .0005). Compared with LDL(+), LDL(-) displayed enhanced cytotoxic effects on cultured human umbilical vein endothelial cells, as shown by lactate dehydrogenase assay (P < .003; n = 6), neutral red uptake (P < .02; n = 6), and morphological studies. We also studied the relationship of LDL(-) to age and plasma lipid levels in 133 subjects. The percentage of contribution of LDL(-) to total plasma LDL correlated with age (P < .05), total cholesterol (P < .05), and LDL cholesterol (P < .003). In conclusion, this study shows that LDL(-), a circulating human plasma LDL, is an electronegative native LDL subfraction with cytotoxic effects on endothelial cells. This subfraction, which correlates positively with common atherosclerotic risk factors, might induce atherogenesis by actively contributing to alteration of the vascular endothelium.
Collapse
Affiliation(s)
- K Demuth
- Laboratoire de Biochimie, Hôpital Broussais, Paris, France
| | | | | | | | | | | | | |
Collapse
|
24
|
Demuth K, Myara I, Chappey B, Vedie B, Moatti N. Electronegative LDL subfraction isolated from human plasma by anionexchange FPLC is not an oxidized LDL subfraction. Atherosclerosis 1995. [DOI: 10.1016/0021-9150(95)96538-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Myara I, Pico I, Vedie B, Moatti N. A method to screen for the antioxidant effect of compounds on low-density lipoprotein (LDL): illustration with flavonoids. J Pharmacol Toxicol Methods 1993; 30:69-73. [PMID: 8298183 DOI: 10.1016/1056-8719(93)90009-4] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
We used a recently described anion-exchange chromatographic method (Vedie et al. J Lipid Res 1991;32:1359) to study the protective effect of potential inhibitors of low-density lipoprotein (LDL) oxidation mediated by cupric ion. By way of an example, we studied eight flavonoids (flavone, 3-hydroxyflavone, chrysin, galangin, fisetin, morin, quercetin, and myricetin) as well as three non-flavonoid antioxidants, butylated hydroxytoluene (BHT), probucol, and vitamin C, as reference compounds. Each compound was tested at various concentrations (1-100 microM). For flavonoid concentrations of 10 microM, an index was calculated as the (LDL control-flavonoid)/(LDL control-probucol) ratio, in which each term is expressed as the percentage of the most electronegative LDL fraction (fraction E). If the index is positive, the flavonoid inhibits LDL oxidation. A value > 1 (3-hydroxyflavone and galangin) means greater activity than probucol, whereas a value < 1 means lower activity (fisetin). If the index is around 0 (flavone and chrysin), the flavonoid is inactive. Finally, a negative value reflects possible prooxidant activity (morin, quercetin, and myricetin). Our results show that this chromatographic method can be applied to screening new pharmacological agents for activity against LDL oxidation.
Collapse
Affiliation(s)
- I Myara
- Laboratoire de Biochimie Appliquée, Faculté des Sciences Pharmaceutiques et Biologiques, Châtenay-Malabry, France
| | | | | | | |
Collapse
|
26
|
Vedie B, Myara I, Pech MA, Maziere JC, Maziere C, Caprani A, Moatti N. Fractionation of charge-modified low density lipoproteins by fast protein liquid chromatography. J Lipid Res 1991; 32:1359-69. [PMID: 1770318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
We describe a methodology developed to separate different forms of charge-modified low density lipoproteins (LDL) using the fast protein liquid chromatography (FPLC) system from Pharmacia. Lipoproteins were isolated by sequential ultracentrifugation and introduced onto an anion-exchange column (Mono Q HR 5/5). The multistep NaCl gradient elution was optimized and the analytical variables were determined on copper-oxidized LDL. After oxidation by copper for various times (up to 48 h), five forms were obtained (fractions A, B, C, D, and E). Within-run and day-to-day reproducibility were better than 8.6% and 10%, respectively. Protein and cholesterol recovery after the chromatographic separation was good (greater than 82%) and the detection limit was about 1 microgram. The more negative forms of collected LDL were mainly characterized by an increase in the lipid peroxidation product content, a depletion of vitamin E, an alteration of apoB and increased degradation by macrophages. The proposed methodology was applied to the study of LDL modifications generated by human umbilical endothelial cells and the protective effect of antioxidants (vitamin E and probucol).
Collapse
Affiliation(s)
- B Vedie
- Laboratoire de Biochimie, Faculté des Sciences Pharmaceutiques et Biologiques, Chatenay-Malabry, France
| | | | | | | | | | | | | |
Collapse
|
27
|
Vedie B, Myara I, Pech MA, Maziere JC, Maziere C, Caprani A, Moatti N. Fractionation of charge-modified low density lipoproteins by fast protein liquid chromatography. J Lipid Res 1991. [DOI: 10.1016/s0022-2275(20)41966-2] [Citation(s) in RCA: 57] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|